397 results about "Diabetes retinopathy" patented technology

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.

The invention discloses an attention mechanism-based in-depth learning diabetic retinopathy classification method comprising the following steps: a series of eye ground images are chosen as original data samples which are then subjected to normalization preprocessing operation, the preprocessed original data samples are divided into a training set and a testing set after being cut, a main neutralnetwork is subjected to parameter initializing and fine tuning operation, images of the training set are input into the main neutral network and then are trained, and a characteristic graph is generated; parameters of the main neutral network are fixed, the images of the training set are adopted for training an attention network, pathology candidate zone degree graphs are output and normalized, anattention graph is obtained, an attention mechanism is obtained after the attention graph is multiplied by the characteristic graph, an obtained result of the attention mechanism is input into the main neutral network, the images of the training set are adopted for training operation, and finally a diabetic retinopathy grade classification model is obtained. Via the method disclosed in the invention, the attention mechanism is introduced, a diabetic retinopathy zone data set is used for training the same, and information characteristics of a retinopathy zone is enhanced while original networkcharacteristics are reserved.

The invention provides a method of optical imaging comprising providing a sample to be imaged, measuring and correcting aberrations associated with the sample using adaptive optics, and imaging the sample by optical coherence tomography. The method can be used to image the fundus of a human eye to provide diagnostic information about retinal pathologies such as macular degeneration, retinitis pigmentosa, glaucoma, or diabetic retinopathy. The invention further provides an apparatus comprising an adaptive optics subsystem and a two-dimensional optical coherence tomography subsystem.

This invention provides use of a SARM compound or a composition comprising the same in treating a variety of diseases or conditions in a subject, including, inter-alia, a diabetes disease, and / or disorder such as cardiovascular disease, atherosclerosis, cerebrovascular conditions, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy.

The present invention relates to a method of making novel dipeptidyl peptidase-IV ("DPP-IV') inhibitor compounds useful for treating, inter alia, diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, metabolic syndrome (Syndrome X or insulin resistance syndrome), hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of making 3,3,4,4-tetrafluoropyrrolidine, a starting material utilized in the afore-mentioned method for preparing DPP-IV compounds.

The invention discloses an eye fundus image characteristics extraction method for diabetic retinopathy by utilizing an eye fundus image shot by a digital mydriatic-free eye fundus camera. The method comprises the following steps of (1) selecting an RGB channel of the eye fundus image; (2) positioning the optic disk of the eye fundus image; (3) extracting the hard exudate characteristics and the cotton wool spot characteristics of the eye fundus image, generating an extracted eye fundus image if at least one characteristic is discovered, if no characteristic is discovered, extracting microaneurysm characteristics and retinal hemorrhage characteristics, and generating an extracted eye fundus image. The method belongs to a non-intrusive technology, and is simple, rapid, convenient and effective, and the processed image is clear and obvious in symptom, so the diagnosis of a doctor is facilitated.

The present invention provides a fundus image classification method and device of retinopathy. The method comprises a step of obtaining the fundus image of an eye detection patient, a step of preprocessing the fundus image and obtaining a corresponding grey fundus image, a step of extracting a preset image characteristic in the grey fundus image, a step of analyzing the preset image characteristic according to the diabetic retinopathy classification model of the fundus image, and obtaining the classification result of the corresponding fundus image, a step of extracting the preset image characteristic in the preprocessed grey fundus image, and carrying out prediction classification on the above preset image characteristic through the diabetic retinopathy classification model established according to a support vector machine and a deep neural network so as to obtain a final classification result. The artificial participation is not needed in the whole process, the workload of doctors is reduced, the high standard requirement of the medical qualification level of the doctor is reduced, the accuracy of classification is improved, and the method and the device have great significance for specific applications and medical research.

The present invention relates to a method of making novel dipeptidyl peptidase-IV ("DPP-IV') inhibitor compounds useful for treating, inter alia, diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, metabolic syndrome (Syndrome X or insulin resistance syndrome), hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of making 3,3,4,4-tetrafluoropyrrolidine, a starting material utilized in the afore-mentioned method for preparing DPP-IV compounds.

A method and kit for predicting increased risk of sight-threatening diabetic retinopathy which includes isolating genomic DNA from a sample from a diabetic patient. The genetic polymorphism pattern for the genes IL-1A, IL-1B and IL-1RN is then identified in the DNA. The identified pattern is compared with control patterns of known polymorphisms, and patients expressing a genetic polymorphism pattern associated with increased risk of sight-threatening diabetic retinopathy are identified.

A system for the imaging, processing and evaluation of tissues provides prognostic and diagnostic details regarding diseased tissue. A set of quantitative measures were developed and integrated in an image-base analysis software tool designed for OCT images. The system and methods in this invention is significant because it allows assessing the optical properties and structure morphology differences between normal healthy subjects and diabetic patients with retinopathy up to ETDRS level 35 and without retinopathy.

This invention provides reagents and methods for delivering insulin, insulinomimetic agents, and the like to a vertebrate eye via subconjunctival routes, sub-Tenon's routes, or intravitreal routes for treatment of nerve-related vision disorders such as diabetic retinopathy, and formulations useful in the practice of the disclosed methods.

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.

This invention provides a method for treating diabetic retinopathy in a subject afflicted therewith, comprising administering to the subject's eyes a therapeutically effective amount of soluble RAGE or a derivative thereof, thereby treating diabetic retinopathy in the subject. This invention further provides a method for inhibiting the onset of diabetic retinopathy in a subject afflicted therewith, comprising administering a prophylactically effective amount of soluble RAGE or a derivative thereof to the subject's eyes, thereby inhibiting the onset of diabetic retinopathy in the subject.

The invention relates to a deep-learning-based classification and grading method for diabetes retinopathy. For each kind of diabetes retinopathy, lots of ophthalmoscope photographs are prepared; a deep convolution neural network including multi-level neural network architecture is established; the deep convolution neural network is trained based on the lots of ophthalmoscope photographs, so that the final output value of the deep convolution neural network meets a grading result of the ophthalmoscope photographs; and thus disease grading can be carried out by using the trained deep convolution neural network. According to the method provided by the invention, with application of the lots of ophthalmoscope photographs including diagnosis marks, needed features are learned automatically from a training example base by deep learning and grading diagnosis is carried out; and data features for determination and the deep convolution neural network parameters are corrected continuously during the training process, so that the grading accuracy and reliability in a real application scene can be improved substantially.

A fundus camera using infrared light sources, which included an imaging optical path and an optical path for focusing and positioning and two optical paths share a common set of retina objective lens, and a computer-assisted method for retinal vessel segmentation in general and diabetic retinopathy (DR) image segmentation in particular. The method is primarily based on Multiscale Production of the Matched Filter (MPMF) scheme, which together the fundus camera, is useful for non-invasive diabetic retinopathy detection and monitoring.

The invention provides a diabetic retinopathy fundus photography standard image generation method, which comprises the following steps: 1) enabling a collected non-standard fundus image to be generated into a new sample image through a generation model; 2) carrying out local feature extraction on the new sample image; and 3) comparing local features of the non-standard image with local features of a standard image in a discrimination model, if the local features are consistent, outputting the new sample image, that is, the generated standard image, and if the local features are not consistent, adjusting the new sample image. The provided method is simple and effective; the definition of the generated standard image reaches requirement of an intelligent aided diagnosis system; and accuracy of diagnosis is improved.

The invention discloses a diabetic retina eye ground image pathology detection method comprising the following steps: preprocessing a medical eye ground image so as to form a standard eye ground image; dividing areas for the eye ground image so as to form m sub-images of different eye ground areas; using a multilayer area convolution nerve network model to extract an area depth feature vector of the eye ground sub-image; using the area depth feature vector as the LSTM nerve network input, predicting correlations of different areas, and forming an eye ground image global feature vector; finally, using a whole articulamentum and softmax to realize multi-classification detection of the eye ground image. The method is based on retina eye ground images and labels that can be crawled on the internet, uses the correlation between the eye ground image area depth features and the adjacent area, and realizes the diabetic retina eye ground image pathology automatic detection via the convolution nerve network and recursion nerve network algorithms, thus effectively improving the detection accuracy and timeliness.

Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including, but not limited to, malignant melanomas, solid tumors, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, chronic myelogenous leukemia, leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, diabetic retinopathy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocytosis, mast cell leukemia, and diseases caused by PDGFR-α kinase, PDGFR-β kinase, c-KIT kinase, cFMS kinase, c-MET kinase, and oncogenic forms, aberrant fusion proteins and polymorphs of any of the foregoing kinases.

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and / or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and / or premature ejaculation are described.

The invention provides a diabetic retinopathy grade classification method based on deep learning. The diabetic retinopathy grade classification method comprises the steps of: constructing a sample library; removing backgrounds and noise of ophthalmoscope photographs in the sample library; normalizing the images of different brightness and different intensity to the same range by adopting a local mean value subtracting method; adopting random stretching and rotating methods for different samples for data augmentation, and constructing a training set and a test set; training an initial deep learning network model by establishing an input portion architecture, a multi-branch feature transformation portion architecture and an output portion architecture separately; and inputting samples to betested into the trained initial deep learning network model for diabetic retinopathy grade classification. Compared with the traditional processing method, the diabetic retinopathy grade classification method gets rid of the dependence on prior knowledge, and has good generalization ability; and by adopting the designed multiple grades, a small-sized convolution kernel can be used for extracting very tiny lesion features, thereby making the classification results more reliable.

Compound of a compound of formula (1) or a salt, N-oxide, hydrate or solvate thereof, in the preparation of a composition for inhibition of HSP90 activity: wherein ring A is an aromatic or non-aromatic carbocyclic or heterocyclic ring having 5 ring atoms, for example 1,2,3-triazolyl or a 1,2,4-triazolyl or a tetrazolyl ring; and R1 R2 R3 are as defined in the specification are inhibitors of HSP90 and therefore of use in the treatment of, for example, cancers, viral disease, inflammatory diseases such as rheumatoid arthritis, asthma, multiple sclerosis, Type I diabetes, lupus, psoriasis and inflammatory bowel disease; cystic fibrosis angiogenesis-related disease such as diabetic retinopathy, haemangiomas, and endometriosis; or for protection of normal cells against chemotherapy-induced toxicity; or diseases where failure to undergo apoptosis is an underlying factor, or protection from hypoxia-ischemic injury due to elevation of Hsp70 in the heart and brain; scrapie / CJD, Huntingdon's and Alzheimer's disease.

A Diabetic Retinopathy Diagnostic system based on OCT which will map 3-D blood circulation including velocity information with micron-scale resolution in the retina is disclosed here. The system leverages the advancements in telecommunication and device technologies and employs novel Doppler algorithms. For example, the reference arm in the interferometric system can be a fiber-optically integrated Faraday rotating mirror. By way of example, but not limitation, typically, the light in the detection arm of the Michelson interferometer can be measured using a Volume phase holographic dispersion grating. By way of example, but not limitation, the dispersed light can be focused on a line-scan camera or multi-line 2-D camera.

The present invention relates to compositions and methods for treating diabetic retinopathy and other ocular neovascularization diseases. In one embodiment, the composition comprises at least two different siRNA duplexes and a pharmaceutically acceptable carrier. One of the duplexes binds to an mRNA molecule that encodes VEGF, and the other binds to an mRNA molecule that encodes VEGFR2. In another embodiment, the composition further comprises an siRNA duplex that binds to an mRNA molecule that encodes TGFβ1.

The invention discloses an image feature identification method and apparatus, a storage medium, and an electronic apparatus. The method comprises the steps of obtaining an identification request, wherein the identification request is used for requesting to identify image features in a target image; identifying the image features in the target image through a first neural network model, wherein thefirst neural network model is obtained after parameters in a second neural network model are trained through a first training set and a second training set, image features of training images in the first training set are marked, and image features of training images in the second training set are not marked; and returning a first identification result of the first neural network model, wherein the first identification result is at least used for indicating the image features (such as lesion features) identified in the target image. The technical problem of relatively low screening efficiencyof diabetic retinopathy in related technologies is solved.

An application of the receptor fusion protein VEGF in treating eye diseases including the age associated macula lutea lesion, retinosis of diabetic, xanthelasma of diabetic, etc is disclosed.

A non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy to the proliferative form of diabetic retinopathy comprising intravitreally administering to a patient suffering from non-proliferative diabetic retinopathy an effective amount of serine proteinase enzyme sufficient to create, without surgery, a posterior vitreal detachment to prevent or reduce the progression of proliferative diabetic retinopathy in said patient. Also disclosed is a non-surgical method of treating ocular conditions such as retinal ischemia, retinal inflammation, retinal edema tractional retinal detachment, tractional retinopathy, vitreous hemorrhage and tractional maculopathy by intravitreally administering to a patient suffering from one or more of these conditions with an effective amount of a serine proteinase enzyme to reduce or treat that particular ocular condition. Plasmin, microplasmin and miniplasmin are preferred serine proteinase enzymes and plasmin is the most preferred.

The invention discloses a diabetic retinopathy detection system based on serial structure segmentation. wherein the fundus image acquisition device is used for acquiring a retina fundus image; the data processing device is used for analyzing and processing the acquired fundus image; A data processing apparatus includes: a data processor; Preprocessing function module, Blood vessel segmentation function module, Visual disc segmentation function module, Centrally recessed determination function module, Exudation segmentation function module, and the statistical calculation function module and the doctor diagnosis function module. The data processing device is used for counting the exudation area and calculating the probability of diabetic macular edema lesions in the input fundus image, andfinally, a final diagnosis and treatment scheme is given by combining a statistical calculation result and the fundus doctor according to the divided exudation area and disease probability and combining with the specialty of the fundus doctor. Various related physiological structures of the fundus are systematically considered, a lesion area is segmented, then a diagnosis report is given by a fundus doctor, detection is efficient, lesion detection is more accurate, the workload of the doctor can be greatly reduced, and the working efficiency is improved.

RNA interference, is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.

The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).